Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.243-247, 2005 |
||
Title: Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study | ||
Author: J., MARDIAK ; T., SALEK ; Z., SYCOVA-MILA ; J., OBERTOVA ; Z., HLAVATA ; M., MEGO ; M., RECKOVA ; I., KOZA ; | ||
Abstract: The aim of the study was to determine the efficacy and toxicity of
gemcitabine, cisplatin and paclitaxel (GCP) combination
as a first salvage treatment of patients with relapsed GCT.
Four courses of paclitaxel 175 mg/m2 and cisplatin 50 mg/m2, both
on day 1, and gemcitabine 1000 mg/m2, on days 1 and
8, every 3 weeks, were given to 12 consecutive patients who had
failed standard 1st line treatment.
Six patients (50%; 95% CI 21–79%) achieved favourable response and
two of them are maintained 38+ and 29+ months.
Median survival time was 16 months (range, 0.77–38+). All, but two
patients had hematological toxicity Gr3–4 with infectious
complication seen only in 6 courses of therapy. GCP is an active
second-line combination regimen for relapsed GCTs
with acceptable toxicity profile. However the results of this
study did not show expected treatment efficacy and we raise the
idea of cisplatin dosage relevance in this combination.
|
||
Keywords: germ cell tumors, salvage chemotherapy, paclitaxel, gemcitabine, cisplatin | ||
Year: 2005, Volume: 52, Issue: | Page From: 243, Page To: 247 | |
|
download file |
|